基于MRI的影像组学列线图可能预测局部晚期鼻咽癌诱导化疗反应和生存
本研究纳入123例鼻咽癌患者(训练集100例、验证集23例),基于联合T1加权、T2加权和增强T1加权MRI提取的影像组学特征构建列线图,用于预测诱导化疗反应和生存。影像组学列线图在验证集的C-index为0.863,优于临床列线图的0.549(p<0.01);诱导化疗应答者的3年无进展生存率为84.81%,高于无应答者的39.75%(p<0.001)。
要点
- 基于多参数MRI的影像组学列线图可能有助于鼻咽癌诱导化疗反应预测和风险分层。
- 影像组学列线图在验证集预测诱导化疗反应的C-index为0.863,优于临床列线图0.549。
- 影像组学特征定义的低风险组3年无进展生存率76.24%,高于高风险组48.04%(p<0.05)。
核心结论
- 基于多参数MRI的影像组学可能有助于接受诱导化疗的鼻咽癌患者的个体化风险分层和治疗。
研究设计与样本
- 研究纳入123例鼻咽癌患者,训练集100例、验证集23例,均有多参数MRI图像。
- 影像组学列线图通过整合临床数据与支持向量机生成的影像组学特征构建。
- 影像组学特征由联合T1加权、T2加权和增强T1加权MRI图像中筛选的19个特征组成。
诊断标准与关键数值
- 影像组学列线图在验证集预测诱导化疗反应的C-index为0.863,临床列线图为0.549(p<0.01)。
- 诱导化疗应答者3年无进展生存率84.81%,无应答者39.75%(p<0.001)。
- 影像组学特征定义的低风险组3年无进展生存率76.24%,高风险组48.04%(p<0.05)。
临床应用与阅片要点
- 原文结论认为多参数MRI影像组学可能有助于鼻咽癌诱导化疗患者的个体化风险分层和治疗。
- 决策曲线分析显示影像组学列线图具有临床实用性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To establish and validate a radiomics nomogram for prediction of induction chemotherapy (IC) response and survival in nasopharyngeal carcinoma (NPC) patients.
METHODS: One hundred twenty-three NPC patients (100 in training and 23 in validation cohort) with multi-MR images were enrolled. A radiomics nomogram was established by integrating the clinical data and radiomics signature generated by support vector machine.
RESULTS: The radiomics signature consisting of 19 selected features from the joint T1-weighted (T1-WI), T2-weighted (T2-WI), and contrast-enhanced T1-weighted MRI images (T1-C) showed good prognostic performance in terms of evaluating IC response in two cohorts. The radiomics nomogram established by integrating the radiomics signature with clinical data outperformed clinical nomogram alone (C-index in validation cohort, 0.863 vs 0.549; p < 0.01). Decision curve analysis demonstrated the clinical utility of the radiomics nomogram. Survival analysis showed that IC responders had significant better PFS (progression-free survival) than non-responders (3-year PFS 84.81% vs 39.75%, p < 0.001). Low-risk groups defined by radiomics signature had significant better PFS than high-risk groups (3-year PFS 76.24% vs 48.04%, p < 0.05).
CONCLUSIONS: Multiparametric MRI-based radiomics could be helpful for personalized risk stratification and treatment in NPC patients receiving IC.
KEY POINTS: • MRI Radiomics can predict IC response and survival in non-endemic NPC. • Radiomics signature in combination with clinical data showed excellent predictive performance. • Radiomics signature could separate patients into two groups with different prognosis.
引用
- Zhao L, Gong J, Xi Y, et al. MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma. Eur Radiol. 2019. PMID: 31372781. doi:10.1007/s00330-019-06211-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。